Everest Medicines Limited (Everest Medicines) has postponed the release of its shareholder circular for the proposed major and connected acquisition. The document—originally slated for publication on or before 1 June 2026—will now be issued on or before 3 June 2026 to allow additional time for finalising its contents, including the Share Purchase Agreement details, Independent Board Committee recommendations, and advice from the Independent Financial Adviser.
The Extraordinary General Meeting (EGM) to consider the transaction is scheduled for Wednesday, 17 June 2026. Shareholders on record as of that date will be eligible to attend and vote. To determine entitlement, the register of members will be closed from Friday, 12 June 2026 through Wednesday, 17 June 2026, inclusive. Share transfer documents must be lodged with Computershare Hong Kong Investor Services Limited by 4:30 p.m. on Thursday, 11 June 2026.
The announcement was authorised by Chairman and Executive Director Yifang Wu on 29 May 2026. The board currently comprises three Executive Directors, three Non-executive Directors, and three Independent Non-executive Directors.